Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Emily Collins is active.

Publication


Featured researches published by Emily Collins.


Inflammatory Bowel Diseases | 2015

Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease.

Jessica R. Allegretti; Lawrence F. Borges; Matthew Lucci; Matthew S. Chang; Bonnie Cao; Emily Collins; Brian Vogel; Emily Arthur; Danielle Emmons; Joshua R. Korzenik

Background:Care of patients with inflammatory bowel disease (IBD) poses a significant burden to the health-care system. Repeat hospitalization in subgroups of IBD patients seems to be a large part of this issue; however, there are limited data examining the characteristics of these patients. The aim of this study was to characterize admission patterns in patients with IBD at a tertiary-care center and to identify preventable risk factors of 90-day readmission after an index IBD admission. Methods:Retrospective analysis was performed extracting data from an electronic medical record over a 2-year period. Results:Three hundred fifty-six patients were admitted at least once during the 2-year study period for an unplanned IBD-related reason. Of these, 48.9% were admitted once, 38.2% were admitted 2 to 4 times, and 12.9% were admitted 5 or more times during the study period. Patients with any admission within 90 days before index were excluded; n = 33. One hundred two patients had experienced a readmission by 90 days after index admission. Numerous demographic and medical factors were examined for association with readmission. The final Cox model included 3 variables: depression (HR = 1.99, 1.33–3.00), chronic pain (HR = 1.88, 1.14–3.10), and steroid use in the previous 6 months (HR = 1.33, 0.92–2.04). Conclusions:Our findings suggest that patients with depression and chronic pain are at greatest risk for a readmission within 90 days after an initial IBD admission. Disease activity, represented by steroid use in the previous 6 months, was not related to readmission. Addressing these problems in the outpatient setting may reduce future hospitalizations.


Alimentary Pharmacology & Therapeutics | 2017

Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases

Rachel W. Winter; Emily Collins; Bonnie Cao; Madeline Carrellas; Crowell Am; Joshua R. Korzenik

Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti‐tumour necrosis factor‐α (anti‐TNF‐α) medications among patients with IBD.


Gastroenterology | 2015

Sa1247 Risk Factors for Re-Hospitalization Within 90 Days in Patients With Inflammatory Bowel Disease Are Not Related to Disease Activity

Jessica R. Allegretti; Lawrence F. Borges; Matthew Lucci; Matthew S. Chang; Bonnie Cao; Emily Collins; Emily Arthur; Brian Vogel; Danielle Emmons; Joshua R. Korzenik

Background: Previous studies have demonstrated that the care of inflammatory bowel disease (IBD) patients poses a significant burden to the healthcare system. More than one and a half million people in the United States suffer from ulcerative colitis (UC) and Crohns disease (CD) and these patients require more frequent hospital admissions than non-IBD patients, and have an increased average length of stay. Moreover, hospital care for IBD patients has been shown to be twice as expensive as that for non-IBD controls. Repeat hospitalization in subgroups of IBD patients appears to be a large part of this issue, however there is only limited literature examining the characteristics of IBD patients that are associated frequent hospital use. Aims: To characterize admission patterns in patients with IBD at a tertiary care referral center, and identify preventable causes of 90-day readmission after an index IBD admission. Methods: Data was gathered retrospectively from a tertiary-care IBD referral center. Study subjects included all patients age 18 or older with a known diagnosis of IBD, who were admitted at least once between January 1st, 2011 and December 31st, 2012 for a non-elective, IBD-related reason. Hospital billing records were searched using the Research Patient Data Registry. Univariate analysis was performed. A cox proportional hazards model was developed with covariates felt a priori to be related to readmission. Forward selection was performed. Results: 356 patients were admitted at least once during the 2-year study period for an unplanned, IBD-related reason. 208 (58.4%) had CD and 148 (41.6%) had UC. The mean age at time of index admission was 41.7 years (SD +/17). Women accounted for 62% (n = 220). 125 patients had experienced a re-admission by 90 days and no patients were censored prior to 90 days. The initial model contained 19 covariates. Depression and steroid use in the prior 6 months (a marker of active disease) were forced in. After forward selection the final model included four variables, depression (HR=2.06, 1.42-2.98), chronic pain (HR=1.87,1.19-2.94) etoh use (HR=2.43, 1.21-5.29) and Remicade use (HR=1.15, 0.76-1.72).The proportional hazard assumption was then tested on using Martingale residuals for each of the four variables in the final model and all resulted in non-significant p-value. Conclusions: These findings suggests that patients with depression, chronic pain, and who drink alcohol are at greatest risk for a re-admission within 90 days after an initial IBD admission. Disease activity, represented by steroid use in the prior 6 months, was not related to re-admission. Our study identified that comorbid psychiatric disease, chronic pain, and substance abuse are associated with repeat hospitalization. Addressing these problems in the outpatient setting may reduce future hospitalizations in IBD patients. Table 1: Cox Proportional Hazard Model for 90-day Readmission


Gastroenterology | 2016

Tu2010 A Study of a Novel Pilot Program to Address the Psychosocial Needs of IBD Patients: Possible Impact on Disease Outcome and Reduction of Health Care Utilization

Joshua R. Korzenik; Caitlin Hosmer Kirby; Leslee Kagan; Michael Currier; Beth-Ann Norton; Ashwini Nadkarni; Emily Collins; Carolann Gray; Molly Nestor; Lori A. Ashworth


Digestive Diseases and Sciences | 2016

Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery

Edward L. Barnes; Alison Goldin; Rachel W. Winter; Emily Collins; Bonnie Cao; Madeline Carrellas; Crowell Am; Korzenik


Gastroenterology | 2015

Sa1198 Initial Vedolizumab Cohort: Patient Characteristics and Clinical Response

Matthew Lucci; Emily Collins; Bonnie Cao; Madeline Carrellas; Anne Marie Crowell; Justine States; Michael Currier; Beth-Ann Norton; Joshua R. Korzenik


Gastroenterology | 2016

Sa1912 How Great Is the Unmet Therapeutic Need in IBD?: Magnitude and Characteristics of Patients With Inflammatory Bowel Diseases Who Have an “Unmet Need”

Rachel W. Winter; Madeline Carrellas; Emily Collins; Ami Merker; Joshua R. Korzenik


Gastroenterology | 2016

Sa1950 Predictors of Response to First and Second Anti-Tumor Necrosis Factor Agents Among Patients With Inflammatory Bowel Disease

Ronak V. Patel; Edward L. Barnes; Emily Collins; Bonnie Cao; Madeline Carrellas; Anne Marie Crowell; Justine States; Shelley Hurwitz; Joshua R. Korzenik


Gastroenterology | 2015

Tu1993 Sexual Dysfunction in Women With Inflammatory Bowel Disease: A New IBD-Specific Scale

Punyanganie S. de Silva; Aoibhlinn M. O'Toole; Madeline Carrellas; Emily Collins; Joshua R. Korzenik; Deanna Nguyen; Ashwin N. Ananthakrishnan; Sonia Friedman


Gastroenterology | 2015

Sa1179 Higher 25-Hydroxyvitamin D Levels Are Associated With a Greater Likelihood of Remission With Anti-Tumor Necrosis Factor-α Medications Among Patients With Inflammatory Bowel Diseases

Rachel W. Winter; Matthew Lucci; Emily Collins; Bonnie Cao; Madeline Carrellas; Anne Marie Crowell; Joshua R. Korzenik

Collaboration


Dive into the Emily Collins's collaboration.

Top Co-Authors

Avatar

Joshua R. Korzenik

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Bonnie Cao

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Madeline Carrellas

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Matthew Lucci

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Rachel W. Winter

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Brian Vogel

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Danielle Emmons

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Edward L. Barnes

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Emily Arthur

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Lawrence F. Borges

Brigham and Women's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge